TGF-β, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 511-520

  Booth, Adam J ^a   Bishop, D Keith ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

chronic allograft vasculopathy; chronic rejection; CTGF; fibrosis; hypertrophy; IL 17; IL 6; TGF

Indexed keywords

AZATHIOPRINE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN A; INTERLEUKIN 17; INTERLEUKIN 6; LYMPHOCYTE ANTIBODY; STEROID; TRANSFORMING GROWTH FACTOR BETA;

CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CHRONIC CARDIAC ALLOGRAFT REJECTION; CHRONIC GRAFT REJECTION; DISEASE COURSE; FIBROSING ALVEOLITIS; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW;

CONNECTIVE TISSUE GROWTH FACTOR; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954993478     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.33     Document Type: Review

References (133)

1. Lloyd-Jones D, Adams RJ, Brown TM et al.: Heart disease and stroke statistics - 2010 update. A report from the American Heart Association. Circulation 119(3), 480-486 (2009).
2. Keck BM, Bennett LE, Rosendale J, Daily OP, Novick RJ, Hosenpud JD: Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin. Transpl. 35-49 (1999).
3. Waaga AM, Gasser M, Laskowski I, Tilney NL: Mechanisms of chronic rejection. Curr. Opin. Immunol. 12(5), 517-521 (2000).
4. Mehra MR: Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am. J. Transplant. 6(6), 1248-1256 (2006).
5. Mannon RB: Therapeutic targets in the treatment of allograft fibrosis. Am. J. Transplant. 6(5 Pt 1), 867-875 (2006).
6. Valantine H: Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J. Heart Lung Transplant. 23(5 Suppl.), S187-S193 (2004).
7. Weiss MJ, Madsen JC, Rosengard BR, Allan JS: Mechanisms of chronic rejection in cardiothoracic transplantation. Front. Biosci. 13, 2980-2988 (2008).
8. Hornick P, Rose M: Chronic rejection in the heart. Methods Mol. Biol. 333, 131-144 (2006).
9. Bieber CP, Stinson EB, Shumway NE, Payne R, Kosek J: Cardiac transplantation in man. VII. Cardiac allograft pathology. Circulation 41(5), 753-772 (1970).
10. Yeung AC, Davis SF, Hauptman PJ et al.: Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. J. Heart Lung Transplant. 14(6 Pt 2), S215-S220 (1995).
11. Weis M, von Scheidt W: Cardiac allograft vasculopathy: a review. Circulation 96(6), 2069-2077 (1997).
12. Wahlers T, Mugge A, Oppelt P et al.: Coronary vasculopathy following cardiac transplantation and cyclosporine immunosuppression: preventive treatment with angiopeptin, a somatostatin analog. Transplant. Proc. 26(5), 2741-2742 (1994).
13. Ewel CH, Foegh ML: Chronic graft rejection: accelerated transplant arteriosclerosis. Immunol. Rev. 134, 21-31 (1993).
14. Li H, Tanaka K, Chhabra A, Oeser B, Kobashigawa JA, Tobis JM: Vascular remodeling 1 year after cardiac transplantation. J. Heart Lung Transplant. 26(1), 56-62 (2007).
15. Raichlin E, Bae JH, Khalpey Z et al.: Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116(23), 2726-2733 (2007).
16. Eisen H: Long-term cardiovascular risk in transplantation - insights from the use of everolimus in heart transplantation. Nephrol. Dial. Transplant. 21(Suppl. 3), III9-III13 (2006).
17. Segovia J, Gomez-Bueno M, Alonso-Pulpon L: Treatment of allograft vasculopathy in heart transplantation. Expert Opin. Pharmacother. 7(17), 2369-2383 (2006).
18. Tullius SG, Tilney NL: Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 59(3), 313-318 (1995).
19. Torre-Amione G, Wallace CK, Young JB et al.: The effect of etanercept on cardiac transplant recipients: a study of TNFa antagonism and cardiac allograft hypertrophy. Transplantation 84(4), 480-483 (2007).
20. Weber KT, Sun Y, Tyagi SC, Cleutjens JP: Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J. Mol. Cell. Cardiol. 26(3), 279-292 (1994).
21. Phan SH: Biology of fibroblasts and myofibroblasts. Proc. Am. Thorac. Soc. 5(3), 334-337 (2008).
22. Kovacs EJ, DiPietro LA: Fibrogenic cytokines and connective tissue production. FASEB J. 8(11), 854-861 (1994).
23. Wu GD, Tuan TL, Bowdish ME et al.: Evidence for recipient derived fibroblast recruitment and activation during the development of chronic cardiac allograft rejection. Transplantation 76(3), 609-614 (2003).
24. Wu GD, Bowdish ME, Jin YS et al.: Contribution of mesenchymal progenitor cells to tissue repair in rat cardiac allografts undergoing chronic rejection. J. Heart Lung Transplant. 24(12), 2160-2169 (2005).
25. Wu GD, Nolta JA, Jin YS et al.: Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 75(5), 679-685 (2003).
26. Sartore S, Chiavegato A, Faggin E et al.: Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ. Res. 89(12), 1111-1121 (2001).
27. Zeisberg EM, Tarnavski O, Zeisberg M et al.: Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13(8), 952-961 (2007).
28. Goumans MJ, van Zonneveld AJ, ten Dijke P: Transforming growth factor b-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc. Med. 18(8), 293-298 (2008).
29. Mazzucchelli L: Protein S100A4: too long overlooked by pathologists? Am. J. Pathol. 160(1), 7-13 (2002).
30. Cook HT: The origin of renal fibroblasts and progression of kidney disease. Am. J. Pathol. 176(1), 22-24 (2010).
31. Humphreys BD, Lin SL, Kobayashi A et al.: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176(1), 85-97).
32. Suzuki J, Isobe M, Aikawa M et al.: Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts. A study in rat and monkey models. Circulation 94(5), 1118-1124 (1996).
33. Ramirez AM, Shen Z, Ritzenthaler JD, Roman J: Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF-β signaling through Smad3-dependent and -independent pathways. Am. J. Transplant. 6(9), 2080-2088 (2006).
34. Eyden B: The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J. Cell. Mol. Med. 12(1), 22-37 (2008).
35. Subramanian SV, Kelm RJ, Polikandriotis JA, Orosz CG, Strauch AR: Reprogramming of vascular smooth muscle a-actin gene expression as an early indicator of dysfunctional remodeling following heart transplant. Cardiovasc. Res. 54(3), 539-548 (2002).
36. Subramanian SV, Orosz CG, Strauch AR: Vascular smooth muscle a-actin expression as an indicator of parenchymal cell reprogramming in cardiac allografts. Transplantation 65(12), 1652-1656 (1998).
37. Serini G, Bochaton-Piallat ML, Ropraz P et al.: The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-b1. J. Cell Biol. 142(3), 873-881 (1998).
38. Muro AF, Moretti FA, Moore BB et al.: An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177(6), 638-645 (2008).
39. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G: Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc. Res. 69(3), 716-725 (2006).
40. Parkes JG, Liu Y, Sirna JB, Templeton DM: Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J. Mol. Cell. Cardiol. 32(2), 233-246 (2000).
41. Brown RD, Ambler SK, Mitchell MD, Long CS: The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 45, 657-687 (2005).
42. Camelliti P, Borg TK, Kohl P: Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65(1), 40-51 (2005).
43. Eghbali M: Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation. Basic Res. Cardiol. 87(Suppl. 2), 183-189 (1992).
44. Camelliti P, Green CR, Kohl P: Structural and functional coupling of cardiac myocytes and fibroblasts. Adv. Cardiol. 42, 132-149 (2006).
45. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ. Res. 62(4), 757-765 (1988).
46. Weber KT, Jalil JE, Janicki JS, Pick R: Myocardial collagen remodeling in pressure overload hypertrophy. A case for interstitial heart disease. Am. J. Hypertens. 2(12 Pt 1), 931-940 (1989).
47. Weber KT, Brilla CG: Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res. Cardiol. 87(Suppl. 1), 291-301 (1992).
48. Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT: Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc. Res. 24(9), 741-747 (1990).
49. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc. Res. 27(3), 341-348 (1993).
50. Nicoletti A, Michel JB: Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc. Res. 41(3), 532-543 (1999).
51. Diaz JA, Booth AJ, Lu G, Wood SC, Pinsky DJ, Bishop DK: Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am. J. Transplant. 9(8), 1773-1783 (2009).
52. Torre-Amione G: Cardiac allograft hypertrophy: a new target for therapy, a surrogate marker for survival? Am. J. Transplant. 9(1), 7-8 (2009).
53. Matsui Y, Sadoshima J: Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy. J. Mol. Cell. Cardiol. 37(2), 477-481 (2004).
54. Takahashi N, Calderone A, Izzo NJ Jr, Maki TM, Marsh JD, Colucci WS: Hypertrophic stimuli induce transforming growth factor-b 1 expression in rat ventricular myocytes. J. Clin. Invest. 94(4), 1470-1476 (1994).
55. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK: Connective tissue growth factor promotes fibrosis downstream of TGF-β and IL-6 in chronic cardiac allograft rejection. Am. J. Transplant. 10(2), 220-230 (2010).
56. Csencsits K, Wood SC, Lu G et al.: Transforming growth factor b-induced connective tissue growth factor and chronic allograft rejection. Am. J. Transplant. 6(5 Pt 1), 959-966 (2006).
57. Raichlin E, Villarraga HR, Chandrasekaran K et al.: Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. Am. J. Transplant. 9(1), 132-139 (2009).
58. Libby P, Pober JS: Chronic rejection. Immunity 14(4), 387-397 (2001).
59. Izutani H, Miyagawa S, Shirakura R et al.: Evidence that graft coronary arteriosclerosis begins in the early phase after transplantation and progresses without chronic immunoreaction. Histopathological analysis using a retransplantation model. Transplantation 60(10), 1073-1079 (1995).
60. Jain S, Furness PN, Nicholson ML: The role of transforming growth factor b in chronic renal allograft nephropathy. Transplantation 69(9), 1759-1766 (2000).
61. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-b regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
62. Border WA, Noble NA: Transforming growth factor b in tissue fibrosis. N. Engl. J. Med. 331(19), 1286-1292 (1994).
63. Cucoranu I, Clempus R, Dikalova A et al.: NAD(P)H oxidase 4 mediates transforming growth factor-b1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res. 97(9), 900-907 (2005).
64. Noronha IL, Niemir Z, Stein H, Waldherr R: Cytokines and growth factors in renal disease. Nephrol. Dial. Transplant. 10(6), 775-786 (1995).
65. Zhang HY, Phan SH: Inhibition of myofibroblast apoptosis by transforming growth factor b(1). Am. J. Respir. Cell. Mol. Biol. 21(6), 658-665 (1999).
66. Brattain MG, Markowitz SD, Willson JK: The type II transforming growth factor-b receptor as a tumor-suppressor gene. Curr. Opin. Oncol. 8(1), 49-53 (1996).
67. Massague J, Blain SW, Lo RS: TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103(2), 295-309 (2000).
68. Faust SM, Lu G, Marini BL et al.: Role of T cell TGF-β signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J. Immunol. 183(11), 7297-7306 (2009).
69. Wood KJ, Sakaguchi S: Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3(3), 199-210 (2003).
70. +CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl. Immunol. 17(2), 120-129 (2007).
71. Walsh PT, Taylor DK, Turka LA: Tregs and transplantation tolerance. J. Clin. Invest. 114(10), 1398-1403 (2004).
72. Yamaguchi Y, Mann DM, Ruoslahti E: Negative regulation of transforming growth factor-b by the proteoglycan decorin. Nature 346(6281), 281-284 (1990).
73. Border WA, Noble NA, Yamamoto T et al.: Natural inhibitor of transforming growth factor-b protects against scarring in experimental kidney disease. Nature 360(6402), 361-364 (1992).
74. Zhang Z, Garron TM, Li XJ et al.: Recombinant human decorin inhibits TGF-b1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns 35(4), 527-537 (2009).
75. Pedagogos E, Hewitson TD, Walker RG, Nicholis KM, Becker GJ: Myofibroblast involvement in chronic transplant rejection. Transplantation 64(8), 1192-1197 (1997).
76. Isaka Y, Brees DK, Ikegaya K et al.: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. 2(4), 418-423 (1996).
77. Kolb M, Margetts PJ, Sime PJ, Gauldie J: Proteoglycans decorin and biglycan differentially modulate TGF-b-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 280(6), L1327-1334 (2001).
78. Faust SM, Lu G, Wood SC, Bishop DK: TGF-β neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection. J. Immunol. 183(11), 7307-7313 (2009).
79. Leask A, Abraham DJ: The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell. Biol. 81(6), 355-363 (2003).
80. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH: CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J. Mol. Cell. Cardiol. 32(10), 1805-1819 (2000).
81. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA: Connective tissue growth factor and cardiac fibrosis. Acta Physiol. (Oxf.) 195(3), 321-338 (2009).
82. Kundi R, Hollenbeck ST, Yamanouchi D et al.: Arterial gene transfer of the TGF-β signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc. Res. 84(2), 326-335 (2009).
83. Hayata N, Fujio Y, Yamamoto Y et al.: Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem. Biophys. Res. Commun. 370(2), 274-278 (2008).
84. de Winter P, Leoni P, Abraham D: Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein. Growth Factors 26(2), 80-91 (2008).
85. Bonniaud P, Martin G, Margetts PJ et al.: Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis- resistant" BALB/c mouse lungs. Am. J. Respir. Cell. Mol. Biol. 31(5), 510-516 (2004).
86. Cheng O, Thuillier R, Sampson E et al.: Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am. J. Transplant. 6(10), 2292-2306 (2006).
87. Yuan YC, Xia ZK, Mu JJ, Zhang QC, Yin BL: Increased connective tissue growth factor expression in a rat model of chronic heart allograft rejection. J. Formos. Med. Assoc. 108(3), 240-246 (2009).
88. Csencsits K, Wood SC, Lu G, Bishop DK: Transforming growth factor-b1 gene transfer is associated with the development of regulatory cells. Am. J. Transplant. 5(10), 2378-2384 (2005).
89. Guo X, Wang XF: Signaling cross-talk between TGF-b/BMP and other pathways. Cell Res. 19(1), 71-88 (2009).
90. Bettelli E, Carrier Y, Gao W et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090), 235-238 (2006).
91. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML: Interleukin-6 inhibits transforming growth factor-b-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 274(33), 23013-23019 (1999).
92. Zhang XL, Topley N, Ito T, Phillips A: Interleukin-6 regulation of transforming growth factor (TGF)-b receptor compartmentalization and turnover enhances TGF-b1 signaling. J. Biol. Chem. 280(13), 12239-12245 (2005).
93. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, ODonnell VB: Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 171(1), 315-325 (2007).
94. Jones SA: Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol. 175(6), 3463-3468 (2005).
95. Naugler WE, Karin M: The wolf in sheeps clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 14(3), 109-119 (2008).
96. Van Snick J: Interleukin-6: an overview. Annu. Rev. Immunol. 8, 253-278 (1990).
97. Takatsuki F, Okano A, Suzuki C et al.: Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J. Immunol. 141(9), 3072-3077 (1988).
98. Hurst SM, Wilkinson TS, McLoughlin RM et al.: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6), 705-714 (2001).
99. Lin ZQ, Kondo T, Ishida Y, Takayasu T, Mukaida N: Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J. Leukoc. Biol. 73(6), 713-721 (2003).
100. Youker K, Smith CW, Anderson DC et al.: Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion. J. Clin. Invest. 89(2), 602-609 (1992).
101. Sporri B, Muller KM, Wiesmann U, Bickel M: Soluble IL-6 receptor induces calcium flux and selectively modulates chemokine expression in human dermal fibroblasts. Int. Immunol. 11(7), 1053-1058 (1999).
102. Weissenbach M, Clahsen T, Weber C et al.: Interleukin-6 is a direct mediator of T cell migration. Eur. J. Immunol. 34(10), 2895-2906 (2004).
103. Fielding CA, McLoughlin RM, McLeod L et al.: IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 181(3), 2189-2195 (2008).
104. McLoughlin RM, Jenkins BJ, Grail D et al.: IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc. Natl Acad. Sci. USA 102(27), 9589-9594 (2005).
105. Teague TK, Marrack P, Kappler JW, Vella AT: IL-6 rescues resting mouse T cells from apoptosis. J. Immunol. 158(12), 5791-5796 (1997).
106. Yang XO, Nurieva R, Martinez GJ et al.: Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29(1), 44-56 (2008).
107. +CD25+ T cell regulatory functions. J. Immunol. 178(1), 271-279 (2007).
108. +CD25+ T cell-mediated suppression by dendritic cells. Science 299(5609), 1033-1036 (2003).
109. Zhao XM, Frist WH, Yeoh TK, Miller GG: Expression of cytokine genes in human cardiac allografts: correlation of IL-6 and transforming growth factor-b (TGF-b) with histological rejection. Clin. Exp. Immunol. 93(3), 448-451 (1993).
110. Liang Y, Christopher K, Finn PW, Colson YL, Perkins DL: Graft produced interleukin-6 functions as a danger signal and promotes rejection after transplantation. Transplantation 84(6), 771-777 (2007).
111. Chen L, Ahmed E, Wang T et al.: TLR signals promote IL-6/IL-17-dependent transplant rejection. J. Immunol. 182(10), 6217-6225 (2009).
112. Erten Y, Tulmac M, Derici U et al.: An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients. Ren. Fail. 27(5), 581-589 (2005).
113. Fredj S, Bescond J, Louault C, Potreau D: Interactions between cardiac cells enhance cardiomyocyte hypertrophy and increase fibroblast proliferation. J. Cell. Physiol. 202(3), 891-899 (2005).
114. Kurdi M, Randon J, Cerutti C, Bricca G: Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol. Cell. Biochem. 269(1-2), 95-101 (2005).
115. Sano M, Fukuda K, Kodama H et al.: Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J. Biol. Chem. 275(38), 29717-29723 (2000).
116. Briest W, Rassler B, Deten A et al.: Norepinephrine-induced interleukin-6 increase in rat hearts: differential signal transduction in myocytes and non-myocytes. Pflugers Arch. 446(4), 437-446 (2003).
117. Birks EJ, Burton PB, Owen V et al.: Elevated tumor necrosis factor-α and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 102(19 Suppl. 3), III352-III358 (2000).
118. Hirota H, Izumi M, Hamaguchi T et al.: Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 19(5), 237-241 (2004).
119. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27(5), 1201-1206 (1996).
120. Tsutamoto T, Hisanaga T, Wada A et al.: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 31(2), 391-398 (1998).
121. Vasan RS, Sullivan LM, Roubenoff R et al.: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107(11), 1486-1491 (2003). (Pubitemid 36378485)
122. Sarkar S, Vellaichamy E, Young D, Sen S: Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am. J. Physiol. Heart Circ. Physiol. 287(1), H107-117 (2004).
123. Fredj S, Bescond J, Louault C, Delwail A, Lecron JC, Potreau D: Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J. Cell. Physiol. 204(2), 428-436 (2005). (Pubitemid 40934637)
124. Liu X, Das AM, Seideman J et al.: The CC chemokine ligand 2 (CCL2) mediates fibroblast survival through IL-6. Am. J. Respir. Cell. Mol. Biol. 37(1), 121-128 (2007).
125. Burlingham WJ, Love RB, Jankowska-Gan E et al.: IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Invest. 117(11), 3498-3506 (2007).
126. Fukami N, Ramachandran S, Saini D et al.: Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J. Immunol. 182(1), 309-318 (2009).
127. Simonian PL, Roark CL, Wehrmann F et al.: Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J. Immunol. 182(1), 657-665 (2009).
128. Yuan X, Paez-Cortez J, Schmitt-Knosalla I et al.: A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J. Exp. Med. 205(13), 3133-3144 (2008).
129. Venkatachalam K, Mummidi S, Cortez DM, Prabhu SD, Valente AJ, Chandrasekar B: Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 294(5), H2078-H2087 (2008).
130. Feng W, Li W, Liu W, Wang F, Li Y, Yan W: IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp. Mol. Pathol. 87(3), 212-218 (2009).
131. Cortez DM, Feldman MD, Mummidi S et al.: IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-b , NF-κB, and AP-1 activation. Am. J. Physiol. Heart Circ. Physiol. 293(6), H3356-H3365 (2007).
132. Chabaud M, Fossiez F, Taupin JL, Miossec P: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol. 161(1), 409-414 (1998).
133. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206(7), 1457-1464 (2009).